DE68909542D1 - Viruskonservierung. - Google Patents

Viruskonservierung.

Info

Publication number
DE68909542D1
DE68909542D1 DE89901874T DE68909542T DE68909542D1 DE 68909542 D1 DE68909542 D1 DE 68909542D1 DE 89901874 T DE89901874 T DE 89901874T DE 68909542 T DE68909542 T DE 68909542T DE 68909542 D1 DE68909542 D1 DE 68909542D1
Authority
DE
Germany
Prior art keywords
conservation
virus
virus conservation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89901874T
Other languages
English (en)
Other versions
DE68909542T2 (de
Inventor
Bruce Roser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Bioresources Ltd
Original Assignee
Quadrant Bioresources Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Bioresources Ltd filed Critical Quadrant Bioresources Ltd
Application granted granted Critical
Publication of DE68909542D1 publication Critical patent/DE68909542D1/de
Publication of DE68909542T2 publication Critical patent/DE68909542T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE89901874T 1988-01-21 1989-01-18 Viruskonservierung. Expired - Fee Related DE68909542T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888801338A GB8801338D0 (en) 1988-01-21 1988-01-21 Preservation of viruses

Publications (2)

Publication Number Publication Date
DE68909542D1 true DE68909542D1 (de) 1993-11-04
DE68909542T2 DE68909542T2 (de) 1994-02-03

Family

ID=10630314

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89901874T Expired - Fee Related DE68909542T2 (de) 1988-01-21 1989-01-18 Viruskonservierung.

Country Status (10)

Country Link
US (1) US5149653A (de)
EP (1) EP0357709B1 (de)
JP (1) JPH0671423B2 (de)
AR (1) AR240255A1 (de)
CA (1) CA1333562C (de)
CS (1) CS276472B6 (de)
DE (1) DE68909542T2 (de)
ES (1) ES2009704A6 (de)
GB (1) GB8801338D0 (de)
WO (1) WO1989006542A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759774A (en) * 1988-05-18 1998-06-02 Cobe Laboratories, Inc. Method of detecting circulating antibody types using dried or lyophilized cells
USRE38385E1 (en) 1989-02-16 2004-01-13 Nektar Therapeutics Storage of materials
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5621094A (en) * 1990-05-14 1997-04-15 Quadrant Holdings Cambridge Limited Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
US5200399A (en) * 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
GB9125695D0 (en) * 1991-12-03 1992-01-29 Mastavac Limited Medical preparations
US5422254A (en) * 1992-02-14 1995-06-06 Oy Alko Ab Method to increase the trehalose content of organisms by transforming them with the structural genes for the short and long chains of yeast trehalose synthase
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0679088B1 (de) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonale abgabe von aktiven fragmenten des parathormons
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
DE69426292T2 (de) * 1993-02-23 2001-05-17 Genentech Inc Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
AU689217B2 (en) 1994-03-07 1998-03-26 Novartis Ag Methods and compositions for pulmonary delivery of insulin
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1995033488A1 (en) * 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1996008979A1 (en) 1994-09-22 1996-03-28 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
DE69628007T2 (de) * 1995-06-07 2003-11-27 Elan Drug Delivery Ltd Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US6509146B1 (en) 1996-05-29 2003-01-21 Universal Preservation Technologies, Inc. Scalable long-term shelf preservation of sensitive biological solutions and suspensions
US5876992A (en) 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
DK0967862T3 (da) 1997-02-07 2003-05-12 Elan Drug Delivery Ltd Fremgangsmåde og præparater til fremstilling af tørrede, lagringsstabile blodplader
TW466116B (en) * 1997-03-04 2001-12-01 Hayashibara Biochem Lab Reduction inhibitory agent for active-oxygen eliminating activity, method for inhibiting the reduction of said activity, and composition containing said agent
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
IL124275A (en) 1997-05-02 2002-03-10 Bio Merieux Vitek Inc A method to produce sequences of nucleic acids
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
US6214054B1 (en) 1998-09-21 2001-04-10 Edwards Lifesciences Corporation Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
JP2002542815A (ja) * 1999-05-04 2002-12-17 ワーラル、エリック・エドワード ウイルスおよびマイコプラズマの保存方法
GB9914412D0 (en) * 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
JP2004502641A (ja) 2000-02-10 2004-01-29 ザ　リージェンツ　オブ　ザ　ユニバーシティ　オブ　カリフォルニア 治療用血小板及び方法
US6770478B2 (en) 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7101693B2 (en) * 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
EP1458360B1 (de) 2001-12-19 2011-05-11 Novartis AG Pulmonale verabreichung von aminoglykosiden
US6878168B2 (en) 2002-01-03 2005-04-12 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
US20040057969A1 (en) * 2002-09-20 2004-03-25 Smith Mark L Compositions containing stabilized hepatitis antigen and methods of their use
GB0225520D0 (en) * 2002-11-01 2002-12-11 Glaxosmithkline Biolog Sa Drying process
KR101130948B1 (ko) * 2002-11-01 2012-03-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 건조 공정
US6927062B2 (en) * 2002-11-25 2005-08-09 Agdia, Inc. Controls and standards for assays and method for manufacture thereof
US20050095320A1 (en) * 2003-10-29 2005-05-05 Richard Botteri [An Isotonic Sports Drink for Female Athletes Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Nutrition During Execise and Competition]
US20050100636A1 (en) * 2003-11-10 2005-05-12 Megan Botteri [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity]
EP3167961A1 (de) 2004-04-08 2017-05-17 Biomatrica, Inc. Integration von probenlagerung und probenverwaltung für biowissenschaften
EP1796653A2 (de) * 2004-07-26 2007-06-20 Actelion Pharmaceuticals Ltd. Behandlung von pulmonaler hypertonie durch inhaliertes iloprost mit einer mikroteilchen-formulierung
DE102005003457B4 (de) 2004-07-30 2009-12-03 IfP Privates Institut für Produktqualität GmbH Verfahren und Teilesatz zur mikrobiologischen Bestimmung von Vitamen
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
CN101626682B (zh) 2006-10-27 2014-04-16 爱德华兹生命科学公司 用于外科植入的生物组织
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
US9101691B2 (en) 2007-06-11 2015-08-11 Edwards Lifesciences Corporation Methods for pre-stressing and capping bioprosthetic tissue
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
MX2010003613A (es) * 2007-10-01 2010-04-21 Omnilytics Inc Metodos para secar bacteriofago y composiciones que contienen bacteriofago, las composiciones secas resultantes, y metodos de uso.
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
US8357387B2 (en) 2007-12-21 2013-01-22 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
PL213166B1 (pl) * 2008-10-29 2013-01-31 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Sposób otrzymywania farmakologicznej stabilnej formy zliofilizowanych aktywnych preparatów oczyszczonych bakteriofagów
CA2761675A1 (en) 2009-05-11 2010-11-18 Biomatrica, Inc. Compositions and methods for biological sample storage
JP5548436B2 (ja) * 2009-12-17 2014-07-16 株式会社林原 血液寒天培地及びその保存方法
WO2011119754A2 (en) 2010-03-23 2011-09-29 Edwards Lifesciences Corporation Methods of conditioning sheet bioprosthetic tissue
FR2960781B1 (fr) 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
US8906601B2 (en) 2010-06-17 2014-12-09 Edwardss Lifesciences Corporation Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
EP2598660B1 (de) 2010-07-26 2017-03-15 Biomatrica, INC. Zusammensetzungen zur stabilisierung von dna, rna und proteinen in blut- und anderen biologischen proben während des transports und der lagerung bei umgebungstemperaturen
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012028315A1 (en) 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition
US9351829B2 (en) 2010-11-17 2016-05-31 Edwards Lifesciences Corporation Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability
US11149254B2 (en) 2011-04-15 2021-10-19 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US10238771B2 (en) 2012-11-08 2019-03-26 Edwards Lifesciences Corporation Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
WO2015050177A1 (ja) 2013-10-03 2015-04-09 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3154338B1 (de) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilisierung von thrombozyten bei umgebungstemperatur
CN107614008A (zh) * 2015-03-20 2018-01-19 蓝鸟生物公司 载体制剂
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CN108700498B (zh) 2015-12-08 2021-07-13 生物马特里卡公司 降低红细胞沉降速率
BR112019009113A2 (pt) * 2016-11-04 2019-07-16 Baxalta GmbH formulações de vírus adenoassociado
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
GB8500698D0 (en) * 1985-01-11 1985-02-13 Unilever Plc Preparation of reagents
DE3682047D1 (de) * 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
DE3601922A1 (de) * 1986-01-23 1987-07-30 Behringwerke Ag Stabilisiertes virus-antigen, verfahren zu seiner herstellung und seine verwendung
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) * 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process

Also Published As

Publication number Publication date
JPH0671423B2 (ja) 1994-09-14
JPH02503266A (ja) 1990-10-11
CA1333562C (en) 1994-12-20
DE68909542T2 (de) 1994-02-03
GB8801338D0 (en) 1988-02-17
US5149653A (en) 1992-09-22
EP0357709B1 (de) 1993-09-29
EP0357709A1 (de) 1990-03-14
AR240255A1 (es) 1990-03-30
CS276472B6 (en) 1992-06-17
WO1989006542A1 (en) 1989-07-27
CS40289A3 (en) 1992-01-15
ES2009704A6 (es) 1989-10-01

Similar Documents

Publication Publication Date Title
DE68909542T2 (de) Viruskonservierung.
FI880218A (fi) Oeppnings- och staengningsanordning foer taklucka i fordon.
FI882194A0 (fi) Mellanlagringssystem foer glasskivpar i en vindruteproduktionslinje.
FI881581A (fi) Styrsystem i hydrauliskt manoeverorgan.
FI885772A0 (fi) Ljudisolerande mellanstycke foer bruks- eller vaermningsvattenroersystemet i en byggnad.
ES1006988Y (es) Farola.
ES1007406Y (es) Maceton desarmable.
FI883506A (fi) Stabiliseringsanordning foer dragarmarna i en traktor.
FI883717A (fi) I hjul gripande foerflyttningsanordning.
FI881041A0 (fi) Baerkonstruktion i roterande trumma.
FI881028A0 (fi) Oscilleringsmekanism foer straolroeret i en pappersmaskin.
FI880142A0 (fi) Styrfoerfarande och -system i hydrauliskt manoeverorgan.
FI882139A0 (fi) I maskan faongande kombinationsnaet.
FI890555A (fi) Baerkonstruktion i roterande trumma.
FI882209A0 (fi) Karmprofil foer en foensterkarm i en vaeggkonstruktion.
FI882259A0 (fi) Fleretageinlopslaoda i pappersmaskin.
FI882428A (fi) Anording i rullpackmaskin.
FI883270A0 (fi) Pressparti i pappersmaskin.
FI880505A0 (fi) Skarvar i stockkonstruktioner.
FI883557A (fi) Foerfarande i silktryck.
FI883715A (fi) I boggiehjul gripande foerflyttningsanordning.
FI881555A0 (fi) Behandlingsanordning foer hushaollsvatten foer tryckvattenanlaeggningar i smaofastighet.
FI883906A (fi) Luftkonditioneringsarrangemang i en utrymmesenhet.
FI883922A0 (fi) Hybridformare i en pappersmaskin.
FI884025A (fi) Foerkross foer i saeden befintligt smolk.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee